Clinical Trial Detail

NCT ID NCT02244489
Title Momelotinib Combined With Capecitabine and Oxaliplatin in Adults With Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements no
Sponsors Gilead Sciences
Indications

pancreatic adenocarcinoma

Therapies

Capecitabine

Oxaliplatin

Momelotinib

Age Groups: adult

No variant requirements are available.